Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

ATLANTIC Investigators

    Research output: Contribution to journalArticlepeer-review

    322 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study'. Together they form a unique fingerprint.

    Medicine & Life Sciences